Head-To-Head Survey: Zenas BioPharma (NASDAQ:ZBIO) vs. Chemomab Therapeutics (NASDAQ:CMMB)

Chemomab Therapeutics (NASDAQ:CMMB) and Zenas BioPharma (NASDAQ:ZBIO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability.

Profitability

This table compares Chemomab Therapeutics and Zenas BioPharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Chemomab Therapeutics	N/A	-110.78%	-93.27%
Zenas BioPharma	N/A	-73.55%	-57.60%

Risk and Volatility

Chemomab Therapeutics has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500. Comparatively, Zenas BioPharma has a beta of -1.45, indicating that its stock price is 245% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations for Chemomab Therapeutics and Zenas BioPharma, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chemomab Therapeutics	1	1	2	0	2.25
Zenas BioPharma	1	1	6	0	2.63

Chemomab Therapeutics currently has a consensus price target of $26.50, suggesting a potential upside of 1,577.22%. Zenas BioPharma has a consensus price target of $43.14, suggesting a potential upside of 106.62%. Given Chemomab Therapeutics’ higher probable upside, analysts clearly believe Chemomab Therapeutics is more favorable than Zenas BioPharma.

Insider & Institutional Ownership

46.1% of Chemomab Therapeutics shares are owned by institutional investors. 11.9% of Chemomab Therapeutics shares are owned by company insiders. Comparatively, 16.5% of Zenas BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Chemomab Therapeutics and Zenas BioPharma”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chemomab Therapeutics	N/A	N/A	-$13.94 million	($2.96)	-0.53
Zenas BioPharma	$5.00 million	224.17	-$156.99 million	($7.07)	-2.95

Chemomab Therapeutics has higher earnings, but lower revenue than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Chemomab Therapeutics, indicating that it is currently the more affordable of the two stocks.

About Chemomab Therapeutics

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

About Zenas BioPharma

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.